HIP-15: Topical TRH as a Non-Drug Hair Growth-Stimulatory Agent

Voting ended about 2 years agoFailed

Attention HairForce ! I am hereby proposing the second collaboration between HairDAO and Cutaneon, who also developed our T34 treatment. The brief concept is to develop a hair follicle-targeting vehicle that delivers a therapeutically effective dose of thyrotropin-releasing hormone (TRH) in order to stimulate hair growth and/or reduce hair loss.

TRH is expected to be synergistic with our existing Thyroid Hormone treatment as it operates within the same hypothalamus-pituitary-thyroid axis yet it operates via a completely different mechanism of action. Thus, we believe TRH will be additive to our Thyroid Hormone Treatment.

The terms of the agreement with Cutaneon are as follows:

Cutaneon receives 256.5 K € for one year of research

135K € payable upon contract signature
40.5K* € payable after Milestone 1 Interim Report
40.5K € payable after Milestone 2 Interim Report
40.5K € payable after receipt of Final Report

HairDAO owns 95% of the IP generated by the study

HairDAO has the option to purchase the remaining 5% of the IP from Cutaneon with a 10x cap on valuation.

For additional information on the concept and strategy behind this study, please read the document linked below and/or watch the episode of the Hairy Matters podcast linked below:

Off-Chain Vote

For

58.53K vHAIR100%

Against

0 vHAIR0%

Abstain

0 vHAIR0%

Quorum:78%

Download mobile app to vote

Timeline

Nov 28, 2023Proposal created

Nov 28, 2023Proposal vote started

Dec 01, 2023Proposal vote ended

Mar 28, 2025Proposal updated